AMEND news in Tag: selpercatinib
-
Selpercatinib – Can you Help?
AMEND is preparing a patient group submission for the Scottish Medicine's Consortium for the assessment of selpercatinib for use in metastatic MTC with the hope of getting it approved. Can you help us by sending us your input?
Click here for more information
-
Selpercatinib Approved for Metastatic MTC
In September, selpercatinib (also known as LOXO) was approved in England (Cancer Drugs Fund) and Scotland (Interim Basis) for use in metastatic RET-mutation medullary thyroid cancer (MTC) as well as other RET-fusion positive thyroid cancers.